BD Announces Launch of XTRACT Registry to Evaluate Rotarex™ Atherectomy System for Peripheral Artery Disease Treatment

Reuters
28 May
BD Announces Launch of <a href="https://laohu8.com/S/XTR.UK">XTRACT</a> Registry to Evaluate Rotarex™ Atherectomy System for Peripheral Artery Disease Treatment

BD (Becton, Dickinson and Company) has announced the initiation of a patient data registry for the Rotarex™ Atherectomy System, aimed at assessing real-world outcomes in the treatment of peripheral artery disease (PAD). Known as the "XTRACT Registry," this study will evaluate the clinical performance of the system in U.S. patients with PAD lesions. The registry is a prospective, multi-center, single-arm, post-market study, expected to enroll up to 600 patients across approximately 100 clinical sites in the United States. Co-Principal Investigators Dr. Prakash Krishnan and Dr. Todd Berland will lead the study, with patient follow-ups scheduled at 30 days, 6 months, and 12 months post-procedure to assess safety and effectiveness. The Rotarex™ Atherectomy System is a minimally invasive device designed for removing plaque and thrombus in peripheral arteries, with dual indications as both an atherectomy and thrombectomy tool.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: NY96966) on May 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10